Vancouver, BC - TheNewswire - June 2, 2021 - AREV NANOTEC BRANDS INC. (CNSX:AREV.CN) (OTC:AREVF) (“AREV”) is pleased to announce the appointment of Dr. Harold C. Smith to its Scientific Advisory Board.
Dr. Harold Smith is the founder, CEO, and president of OyaGen, Inc. (“OyaGen”), a biotechnology company developing therapeutics for infectious diseases and cancer. Dr. Smith also is a full professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine.
Mike Withrow, CEO, stated, “We are pleased to have Dr. Smith join our Scientific Advisory Board. He adds another dimension of knowledge and ability to our growing SAB via his vast experience in life sciences and drug development. His expertise complements our therapeutics, distribution, pharmaceutical distribution/acquisition, and drug discovery platforms.”
“Harold Smith is a unique talent given his technical acumen, orientation and his understanding of problem solving the ‘Business of basic research and medical Sciences’. Dr. Smith has led successful, internal capital rounds as well as directed several major government grants, including significant awards of non-dilutive funding from the National Institutes of Allergies and Infectious Disease, Division of AIDS, National Institutions of Health (“NIH”), for research and development programs. OyaGen has recently licensed its antiviral lead SARS-CoV-2 therapeutic candidate, TNX3500, to Tonix Pharmaceutical Holdings Corp for development and commercialization. He will be a strong asset on the AREV SAB,” stated Kevin Phelps, Board Chairman of OyaGen and a Director of AREV. Under Dr. Smith’s leadership, OyaGen has discovered and patented first-in-class lead (Irino-L) that enables innate immunity against HIV as a treatment with curative potential for HIV/AIDS. In addition, OyaGen’s laboratory, platform of cell and gene engineering technologies, and broad technical knowhow has enabled the development of a cancer drug discovery platform based on gene editing enzymes.
Dr. Smith said, “This is a very exciting and welcome opportunity to participate in the ideation of therapeutics addressing global healthcare needs. I am looking forward to contributing to the Scientific Advisory Board and help drive the critical thinking on testing to quantify the potential physiological benefits of therapeutics in development using biochemical and immunological endpoints. The pairing of AREV’s commercialization goals with my many years of biomedical experience will be a powerful combination for developing and commercializing new therapeutics.”
OyaGen is located in Rochester, New York, in a state-of-the-art laboratory within the Rochester BioVenture Center.
The company has issued 150,000 stock options to Directors, Officers and Consultants of the Company at a price of $0.17 for a period of 5 years from the issued date. These options will vest immediately.
For further information, contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information visit www.arevlifesciences.com
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV NanoTec Inc.
AREV NanoTec Brands Inc. (“AREV”) produces and sells functional ingredients produced via its proprietary extraction systems. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition markets for both the human and pet market. AREV’s model is to toll process extraction of targeted essential and functional oils and license its formulations to Licensed Producers in Canada. The company utilizes toll processors in foreign countries to encapsulate and package its formulations that can be sold in traditional distribution channels and online.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2021 TheNewswire - All rights reserved.
